[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-404220-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-404220-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ias-newsletter-2026-oral-and-injectable-prep-for-men-who-travel-for-work-in-south-africa-and-uganda-mobile-men-six-monthly-newsletter","IAS Newsletter 2026 - Oral and Injectable PrEP for Men Who Travel for Work in South Africa and Uganda - Mobile Men Six-Monthly Newsletter","","IAS Newsletter 2026 summarizes Mobile Men’s six-monthly initial results on delivering oral and injectable PrEP to HIV-negative men who travel for work in South Africa and Uganda. The project compared daily and event-based oral regimens with long-acting injectable CAB-LA, reporting trial design, primary and secondary endpoints, and randomized-phase outcomes. Findings highlight feasible same-day HIV testing and CAB-LA initiation, higher persistence with CAB-LA, and community-focused dissemination of results alongside upcoming cost-effectiveness and qualitative work.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ias-newsletter-2026-oral-and-injectable-prep-for-men-who-travel-for-work-in-south-africa-and-uganda-mobile-men-six-monthly-newsletter/404220/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ias-newsletter-2026-oral-and-injectable-prep-for-men-who-travel-for-work-in-south-africa-and-uganda-mobile-men-six-monthly-newsletter/404220.png","ImageObject",300,407,{"name":42,"@type":43},"lilac","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-27",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Who is the Mobile Men PrEP study targeting in South Africa and Uganda?","Question",{"text":63,"@type":64},"The study focuses on HIV-negative men who travel for work. In South Africa, it mainly includes taxi and truck drivers, while in Uganda it includes fishermen and people working in the fishing industry.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were oral and injectable PrEP options evaluated in the trial?",{"text":68,"@type":64},"Phase 1 randomized 400 HIV-negative men to oral or injectable PrEP for 9 months. Phase 2 was a choice phase where men selected which type of PrEP they wanted to use for 9 months.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key results regarding persistence and preferences for CAB-LA versus oral PrEP?",{"text":72,"@type":64},"Same-day HIV testing and CAB-LA initiation were highly acceptable and feasible for mobile men. CAB-LA users showed about 2.5× higher odds of persisting on PrEP than oral users, and at month 9, 58% chose CAB-LA versus 42% oral PrEP.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},404220,1790648929,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":97,"preview_page_count":4},3985747861865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","IAS Newsletter 2026  \nOral and Injectable PrEP for men who travel for work in South  \nAfrica and Uganda  \nWelcome to the MOBILE MEN six-monthly newsletter – we have initial RESULTS!  \nFor the past 3 years, we have been exploring how to deliver oral and injectable PrEP to men who travel for work. In East London and KwaZulu-Natal in South Africa, this mainly comprises taxi and truck drivers, whilst in Masaka, Uganda, this is focused on fishermen and people working in the fishing industry.  \nFor oral PrEP, men could choose to use daily or event-based (2+1+1) regimens.  \nHow was the trial designed?  \nPhase 1: Randomisation: 400 HIV negative men were randomised to oral or injectable PrEP for 9 months.  \nPhase 2: Choice Phase: men choose what type of PrEP they wanted to use for 9 months.  \nWhat were study endpoints?  \nPrimary: Persistence on PrEP and PrEP choices  \nSecondary: Attitudes and preferences towards PrEP options, cost-effectiveness, HIV self-test, STI, HIV.  \nKey results from the randomised phase of study  \nPresented by Dr Eugene Ruzagira at IAS conference 29th July:  \n• Same-day HIV testing and CAB-LA initiation has highly acceptable and feasible for mobile men in Uganda and South Africa.  \n• CAB-LA users had approx. 2.5× higher odds of persisting on PrEP compared with oral PrEP users  \n• At month 9, 58% of men chose CAB-LA vs 42% oral PrEP (p=0 .01); the proportion choosing CAB-LA was lower than reported in other high-risk populations  \n• Among oral PrEP users, event-based PrEP (alone or combined with daily) was preferred to dailyonly dosing overall.  \n• Event-driven dosing predominated in South Africa compared to Uganda  \nDr Eugene Ruzagira presenting at IAS conference, Rio, Brazil.  \nAlso, please see our poster entitled“PrEP Beyond Prevention: Negotiating social lives, responsibility and risk: Insights from South Africa & Uganda”TUPED297  \nOur thoughts  \nThe study demonstrates that having choice matters. Long-acting injectable CAB-LA achieved higher persistence and was preferred overall; however, many men continued to prefer oral PrEP, particularly event-driven dosing. This suggests that expanding access to a range of PrEP options will be essential to reaching diverse populations and ensuring that HIV prevention services are responsive to men’spreferences and circumstances.  \nResults dissemination with communities  \nA key milestone for Mobile Men was the dissemination of study findings to participating communities in South Africa and Uganda. The results were shared with communities almost at the same time as they were presented at AIDS 2026, ensuring equitable and timely access to study outcomes. These dissemination events provided an opportunity to acknowledge participants' contributions, discuss the findings, and reinforce the study's commitment to community-centred research.  \nResults yet to come  \n- Cost-effectiveness and modelling of oral v injectable PrEP  \n- Interviews and focus group discussions with participants and local communities  \nContact information  \nJulie Fox, MOBILE MEN Project Director, [julie.fox@kcl.ac.uk](julie.fox@kcl.ac.uk)[ ](julie.fox@kcl.ac.uk)Website: MOBILE MEN-King's College London ([kcl.ac.uk](kcl.ac.uk))","cbCaimndhDGQbSRt","https://ap.wps.com/l/cbCaimndhDGQbSRt","pdf",423499,"English","# Trial design and endpoints\n## Randomisation phase\n## Choice phase\n## Primary and secondary endpoints\n# Key results from the randomized phase\n## Testing and CAB-LA initiation feasibility\n## Persistence and preferences\n## Oral PrEP dosing preferences\n# Study implications and dissemination\n## Why choice matters\n## Community results dissemination\n# Results yet to come\n## Cost-effectiveness and modelling\n## Interviews and focus groups\n# Contact information","[{\"question\":\"Who is the Mobile Men PrEP study targeting in South Africa and Uganda?\",\"answer\":\"The study focuses on HIV-negative men who travel for work. In South Africa, it mainly includes taxi and truck drivers, while in Uganda it includes fishermen and people working in the fishing industry.\"},{\"question\":\"How were oral and injectable PrEP options evaluated in the trial?\",\"answer\":\"Phase 1 randomized 400 HIV-negative men to oral or injectable PrEP for 9 months. Phase 2 was a choice phase where men selected which type of PrEP they wanted to use for 9 months.\"},{\"question\":\"What were the key results regarding persistence and preferences for CAB-LA versus oral PrEP?\",\"answer\":\"Same-day HIV testing and CAB-LA initiation were highly acceptable and feasible for mobile men. CAB-LA users showed about 2.5× higher odds of persisting on PrEP than oral users, and at month 9, 58% chose CAB-LA versus 42% oral PrEP.\"}]","IAS Newsletter 2026 - Oral and Injectable PrEP for Men Who Travel for Work in South Africa and Uganda - Mobile Men Six-Monthly Newsletter | PDF",1790546370]